|
業務類別
|
Biotechnology |
|
業務概覽
|
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role. |
| 公司地址
| 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402 |
| 電話號碼
| +1 650 561-8600 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.sagimet.com |
| 員工數量
| 16 |
| Dr. Andreas Grauer, M.D. |
Chief Medical Officer |
-- |
21/04/2026 |
| Mr. David Happel |
Director, Chief Executive Officer and President |
美元 630.00K |
21/04/2026 |
| Mr. Thierry Chauche |
Chief Financial Officer and Principal Accounting Officer |
-- |
21/04/2026 |
| Ms. Elizabeth Rozek, Esq. |
Chief Legal Officer and Chief Administrative Officer |
美元 483.33K |
21/04/2026 |
|
|
| Mr. Paul W. Hoelscher |
Independent Director |
21/04/2026 |
| Dr. Beth C. Seidenberg,M.D. |
Lead Independent Director |
21/04/2026 |
| Mr. David Happel |
Director, Chief Executive Officer and President |
21/04/2026 |
| Mr. Timothy P. Walbert |
Independent Director |
21/04/2026 |
| Mr. George Kemble, PhD |
Executive Chairman of the Board |
21/04/2026 |
| Ms. Elizabeth Grammer, Esq. |
Independent Director |
21/04/2026 |
| Dr. Anne M. Phillips, M.D. |
Independent Director |
21/04/2026 |
| Ms. Jennifer Ann Jarrett |
Independent Director |
21/04/2026 |
|
|
|
|
